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Purine and pyrimidine metabolism: 
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Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly used drugs for the treatment of 
psychiatric diseases including major depressive disorder (MDD). For unknown reasons a substantial 
number of patients do not show any improvement during or after SSRI treatment. We treated DBA/2J 
mice for 28 days with paroxetine and assessed their behavioral response with the forced swim test 
(FST). Paroxetine-treated long-time floating (PLF) and paroxetine-treated short-time floating (PSF) 
groups were stratified as proxies for drug non-responder and responder mice, respectively. Proteomics 
and metabolomics profiles of PLF and PSF groups were acquired for the hippocampus and plasma to 
identify molecular pathways and biosignatures that stratify paroxetine-treated mouse sub-groups. 
The critical role of purine and pyrimidine metabolisms for chronic paroxetine treatment response in the 
mouse was further corroborated by pathway protein expression differences in both mice and patients 
that underwent chronic antidepressant treatment. The integrated -omics data indicate purine and 
pyrimidine metabolism pathway activity differences between PLF and PSF mice. Furthermore, the 
pathway protein levels in peripheral specimens strongly correlated with the antidepressant treatment 
response in patients. Our results suggest that chronic SSRI treatment differentially affects purine and 
pyrimidine metabolisms, which may explain the heterogeneous antidepressant treatment response 
and represents a potential biosignature.
Although Selective Serotonin Reuptake Inhibitors (SSRIs) have been used as preferred antidepressant medica-
tions for several decades, over one third of major depressive disorder (MDD) patients do not respond to SSRI 
treatment1. The high variability in response to SSRIs combined with a lack of clinically useful assessments that 
can reliably determine whether a patient responds to a particular antidepressant compound currently prevent a 
strategic treatment and personalized medicine approach in psychiatry.
The identification of genetic factors that could assist in the prediction and determination of an individual’s 
drug response has been a major focus in psychiatry research. However, despite great efforts in large genome-wide 
association studies, the results are fairly modest. Few genetic polymorphisms identified have achieved 
genome-wide significance or were consistently replicated across studies, suggesting that alternative strategies 
need to be explored to realize molecular stratification of antidepressant treatment response2,3. Both, biomarkers 
determining a priori whether an individual patient responds to the treatment of choice as well as a distinction of 
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responders and non-responders during antidepressant therapy can have a significant impact to achieve this goal. 
Biosignatures including proteins and metabolites would not only allow to monitor treatment response in clinical 
practice, but also assist in the evaluation of drug actions at an early stage in clinical trials which are frequently 
marred by late attrition.
Recent findings obtained with clinical specimens indicate a potent role of metabolites for separating antide-
pressant responder and non-responder patients. Baseline plasma levels of 3-methoxy-4-hydroxyphenylglycol, 
a noradrenaline metabolite, were different between paroxetine responder and non-responder patients4. Several 
pathways involved in dihydroxyphenylacetic acid, serotonin, and gamma tocopherol synthesis have been impli-
cated in separating sertraline responder and non-responder patients5. However, despite these promising findings 
with peripheral patient specimens an understanding of the molecular changes in response to SSRI treatment 
occurring in the brain is still missing. A systematic investigation of affected pathways in the brain and a corre-
lation with the periphery will eventually allow the implementation of biosignatures capable of differentiating 
antidepressant responders and non-responders.
In the current study, a great number of inbred DBA/2J mice were treated for 28 days with a commonly 
used SSRI, paroxetine. The DBA/2J mouse strain was previously shown to be responsive to oral treatment with 
paroxetine under basal stress-free conditions6. Animals were stratified into long-time floating (PLF) and 
short-time floating (PSF) groups according to their forced swim test (FST) floating time. Metabolite profiles in 
the hippocampus and plasma of the PLF and PSF mice were assessed, and hippocampal protein profiles were inte-
grated to identify pathways pertinent for the chronic paroxetine treatment response. We followed up our studies 
in the mouse with an analysis of specimens from patients that underwent chronic antidepressant treatment. We 
found that affected pathways identified in the mouse were also implicated in peripheral blood mononuclear cells 
(PBMCs) from antidepressant non-responder and responder patients.
Results
Sub-grouping of paroxetine responder and non-responder mice. Figure 1a shows a schematic over-
view of the workflow. DBA/2J mice received vehicle or paroxetine pills (2 × 5 mg/kg/day) for 28 days. The par-
oxetine-treated group (PAR) showed significantly reduced FST floating time compared to vehicle-treated (VEH) 
mice (t = 13.90, df = 143, p < 0.0001) (Fig. 1b). We were able to separate paroxetine-treated mice into long-time 
floating (PLF) and short-time floating (PSF) groups according to their FST floating time using hierarchical cluster 
analysis (HCA) (F = 159.5, df = 144, p < 0.001) (Fig. 1c). PSF mice floating time was significantly lower than for 
VEH mice (p < 0.001) while no floating time difference was observed between PLF and VEH mice. During the 
female urine sniffing test (FUST) PLF and PSF mice did not show differential sniffing time prior to paroxetine 
treatment (F(5,192) = 104.5, p > 0.05) (see Supplementary Fig. S1). A slightly different sniffing time became appar-
ent after 28 days of paroxetine treatment (p = 0.052). The time for sniffing female urine was longer for PSF mice 
Figure 1. Sub-grouping of paroxetine-treated mice. (a) A schematic overview of the workflow. (b) Male 
DBA/2J mice received paroxetine (5 mg/kg, twice a day, 28 days) and floating time was recorded for 6 min. 
PAR mice displayed significantly shorter floating time compared to vehicle-treated group (VEH). n(VEH/
PAR) = 50/95. (c) Dendrogram of paroxetine-treated mice. Mice treated with paroxetine were separated 
into PLF and PSF groups using hierarchical clustering analysis (HCA). n(VEH/PLF/PSF) = 50/9/86. Data 
are expressed as mean ± SEM. ***p < 0.001 (one-way ANOVA with Tukey’s test for multiple comparisons), 
****p < 0.0001 (two-tailed t-test).
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compared to VEH and PLF mice (F(5,192) = 84.24, df = 197, p < 0.0001) (see Supplementary Fig. S1). Two-way 
ANOVA identified no interaction between time points and treatment.
Covariates analysis. Covariates that may be relevant for paroxetine treatment response were examined. 
Paroxetine concentration in whole brain and plasma did not differ between groups (p > 0.05) and did not cor-
relate with FST floating time (r = 0.26, p = 0.387) (see Supplementary Fig. S2). We also analyzed mouse age and 
body weight gain. A significant age effect on FST floating time was not observed (F(4,81) = 2.184, p > 0.05) (see 
Supplementary Fig. S2). Body weight gain did not vary between PLF and PSF mice. Both groups had a sig-
nificantly higher body weight gain after chronic paroxetine treatment compared to VEH mice (F(2,42) = 29.51, 
p < 0.0001). Correlation between body weight gain and FST floating time was not significant (VEH: r = − 0.02, 
p = 0.876; PLF: r = − 0.32, p = 0.405; PSF: r = − 0.15, p = 0.169) (see Supplementary Fig. S2).
Chronic paroxetine treatment differentially affects brain and plasma purine and pyrimidine 
metabolism pathways between sub-groups. Brain. After clustering paroxetine-treated mice into 
long-floating and short-floating groups, we performed metabolomics and proteomics analyses of the hippocampus. 
Both -omics analyses showed purine/pyrimidine metabolites and proteins with significant differences between 
the two groups (log2|FC| > 0.3, -log10(p value) > 1.3) (Fig. 2a). In metabolomics analysis, significant analysis of 
microarrays (and metabolites) (SAM) and SAM-driven correlation analysis revealed that chronic paroxetine 
treatment differentially affected the hippocampal metabolome of the PLF and PSF mice (Fig. 2b). Sixteen metab-
olites were differentially regulated showing significantly higher levels in PSF compared to PLF mice (q < 0.05, 
FDR < 0.1). In addition, we found significant correlations with 42 other hippocampal metabolites (r > 0.7, 
FDR < 0.1) (see Supplementary Fig. S3). In proteomics analysis, we found that purine/pyrimidine metabolism 
proteins including S-adenosyl-L-homocysteine hydrolase (AdoHcyase), S-adenosyl-L-homocysteine hydrolase 2 
(AdoHcyase 2), guanine deaminase (GDA), inosine triphosphate pyrophosphatase (ITPase), purine nucleoside 
phosphorylase (PNP) and UMP-CMP kinase (UMP/CMPK) were differentially expressed between the PLF and 
PSF groups (Fig. 2c).
The pyrimidine metabolism pathway was enriched with four metabolites from hippocampal SAM analysis 
(carbamoyl phosphate, dihydroorotate, orotate and thymidine). Eight correlates of SAM signatures (adenine, 
Figure 2. Hippocampal metabolite and protein expression alterations between PLF and PSF mice. (a) A 
volcano plot of hippocampal metabolome and proteome. Metabolites and proteins with log2|FC| > 0.3 and 
-log10(p value) > 1.3 were considered significant. Purine/pyrimidine metabolites and metabolism-related 
proteins were found to be significantly different between the sub-groups. (b) A heat map with combined profiles 
of SAM signatures (q < 0.05, FDR < 0.1) and their significant correlates (r > 0.7, p < 0.05). Heat map colors 
denote normalized metabolite intensity, n = 5/group. (c) Identification of purine and pyrimidine metabolism 
pathway proteins in proteomics analysis. Purine and pyrimidine metabolisms protein levels were significantly 
different between the PLF and PSF mice (p < 0.05), n = 3/group. (d) Metabolomics analysis identified purine 
and pyrimidine metabolisms as affected pathway and sub-pathway, respectively (Holm adjusted p < 0.05, 
FDR < 0.05). (e) Average level difference of purine and pyrimidine metabolites between PLF and PSF group was 
shown by box plots with whiskers min to max. (f) Average purine and pyrimidine pathways metabolite levels 
were strongly correlated with FST floating time. Data are expressed as the mean ± SEM. **p < 0.01, ***p < 0.001, 
****p < 0.0001 (two-tailed t-test). Pearson correlation coefficients (r) with p values are indicated under the 
correlation graphs.
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adenosine 5-phosphosulfate, ADP, dGDP, glutamine, IDP, ppGpp, xanthosine) enriched the purine metabolism 
pathway (Holm adjusted p < 0.05, FDR < 0.05) (Fig. 2d). Average levels of purine and pyrimidine metabolites 
were significantly higher in PSF than PLF mice and were strongly correlated with FST floating time (Fig. 2e,f). 
Purine and pyrimidine metabolite levels were higher in the PSF compared to PLF groups and with the exception 
of adenine and adenosine phosphosulfate showed a significant negative-correlation with FST floating time (see 
Supplementary Fig. S4). Metabolomics analysis of the prefrontal cortex did not result in any metabolite and path-
way differences distinguishing the PLF and PSF groups.
Plasma. To delineate peripheral metabolome changes related to chronic paroxetine treatment response, plasma 
metabolite levels were investigated in the PLF and PSF groups at baseline (T0) and following 28 days of drug treat-
ment (T4). While metabolomic profiles between PLF and PSF groups showed no significant differences both at 
T0 and T4, the PSF group exhibited profound differences with 43 significant metabolite level changes between T0 
and T4 and another 71 metabolites that were strongly correlated (r > 0.7, FDR < 0.1) (see Supplementary Fig. S5). 
In the PSF group pyrimidine metabolism was enriched with 6 metabolites (carbamoyl phosphate, CMP, dTMP, 
thymine, UDP, UMP) and another 7 metabolites (adenosine, AMP, GMP, guanine, hypoxanthine, IMP, uric 
acid) enriched the purine metabolism pathway (Holm adjusted p < 0.05, FDR < 0.05) (Fig. 3a). The PLF group 
exhibited smaller metabolome changes compared to the PSF group. Only 4 metabolites were significantly altered 
after chronic paroxetine treatment according to SAM with another 32 metabolites highly correlated (r > 0.7, 
FDR < 0.1) (see Supplementary Fig. S5). While SAM signatures revealed no significantly affected pathways for 
the PLF group, glycine, serine and threonine metabolism was enriched for 5 correlates (choline, dimethylglycine, 
guanidoacetic acid, serine and threonine) (Holm adjusted p < 0.05, FDR < 0.05) (Fig. 3b). Plasma metabolite 
levels of identified pathways were significantly altered after mice had been treated chronically with paroxetine 
(Fig. 3c–e). Significant purine and pyrimidine metabolite level changes between T0 and T4 were observed only in 
the PSF mice (see Supplementary Fig. S6). Metabolite level changes of glycine, serine and threonine metabolism 
occurred both in PLF and PSF mice (see Supplementary Fig. S6). Plasma metabolite level changes did not show 
a significant correlation with FST floating time except for uric acid (see Supplementary Fig. S7). Seven plasma 
metabolites (2,3-dihydroxzbenzoic acid, aminoadipic acid, choline, pantothenate, taurine, threonine, uracil) were 
common and found to be regulated to a similar extent in both PLF and PSF groups (see Supplementary Fig. S8).
Purine and pyrimidine metabolism pathways protein analysis. Aminoimidazole-4-carboxamide 
ribonucleotide transformylase/IMP cyclohydrolase (ATIC), carbamoyl phosphate synthase 2 (CPS2) and 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) protein expression in the hippocampus, prefrontal 
cortex and erythrocytes were assessed to validate differentially affected pathways between the PLF and PSF groups 
(Fig. 4a, see Supplementary Fig. S9). In the hippocampus, ATIC, CPS2 and HPRT protein levels showed signif-
icant differences between groups. Compared to the PLF group the PSF group had significantly reduced ATIC, 
CPS2 and HPRT protein expression levels (ATIC: t = 3.304, df = 8, p < 0.05, CPS2: t = 1.702, df = 8, p < 0.001, 
HPRT: t = 3.488, df = 8, p < 0.01). In the prefrontal cortex protein expression showed no difference between 
the two groups. For validation of peripheral pathways identified in plasma, erythrocytes were chosen as source. 
Figure 3. Chronic paroxetine treatment induced differential metabolome alterations in plasma. Heat maps 
and identified pathways of (a) PSF and (b) PLF groups comparing metabolome at baseline (T0) and following 
28 days of treatment (T4). Purine and pyrimidine metabolisms were the only affected pathways in the PSF 
group. In the PLF group, correlates of SAM signatures identified glycine, serine and threonine metabolism as a 
sub-pathway (Holm adjusted p < 0.05, FDR < 0.05). Heat map colors denote normalized metabolite intensity, 
n = 5/group. Chronic paroxetine treatment induced average level changes of (c) purine and (d) pyrimidine 
pathways metabolites in the PSF group, and (e) glycine/serine/threonine pathway metabolites in PLF group 
between T0 and T4, n = 5/group. Metabolite levels are expressed with Box plots with whiskers min to max. 
****p < 0.0001 (two-tailed t-test).
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Interestingly, erythrocytic ATIC, CPS2 and HPRT proteins were also differentially expressed between the PLF 
and PSF groups. Erythrocytic ATIC and CPS2 protein expression in the PSF mice was 1.2-fold and 2.4-fold higher 
than in the PLF mice, respectively (ATIC: t = 4.991, df = 8, p < 0.01, CPS2: t = 4.484, df = 8, p < 0.01). HPRT 
protein levels were 1.7-fold higher in the PSF compared to the PLF group (t = 3.145, df = 8, p < 0.05). 
Furthermore, FST floating time significantly correlated with CPS2 and HPRT protein expression levels in the 
hippocampus and erythrocytes, but not in the prefrontal cortex. Correlation between FST floating time and ATIC 
protein levels also showed strong tendency in the hippocampus and erythrocytes (Fig. 4b–d).
Analysis of peripheral patient specimens. Next, we sought to corroborate our findings on pyrimidine 
and purine metabolism in patients chronically treated with antidepressants. For this purpose we carried out 
experiments with PBMCs isolated from patients.
First, the same pyrimidine and purine pathway proteins analyzed in mice, ATIC, CPS2 and HRPT, were 
assessed in PBMCs obtained from antidepressant responder and non-responder patients of the MARS study. In 
PBMCs collected after 4–6 weeks of antidepressant treatment, ATIC and CPS2 protein levels were significantly 
correlated with clinical antidepressant treatment response (ATIC: r = 0.52, p = 0.034; CPS2: r = − 0.69, p = 0.002; 
HPRT: r = − 0.23, p = 0.365) (Fig. 5a).
To further investigate pharmacological effects of paroxetine we also performed ex vivo experiments with 
patients’ PBMCs. Cells collected from patients upon admittance were cultivated and treated with paroxetine for 
2 days. As had been the case for the in vivo PBMCs analysis, ATIC and CPS2 protein levels also significantly cor-
related with patients’ clinical antidepressant response when their cultured PBMCs were treated with paroxetine 
(ATIC: r = − 0.37, p = 0.048; CPS2: r = − 0.39, p = 0.029; HPRT: r = 0.05, p = 0.789) (Fig. 5b).
Figure 4. Chronic paroxetine treatment induces differential alteration of ATIC, CPS2 and HPRT protein 
expression in mice. (a) Western blot and densitometry analyses of CPS2 and HPRT protein levels in the 
hippocampus, prefrontal cortex and erythrocytes. The image represents cropped blots showing the relevant 
protein bands. All gels and blots were run under the same experimental conditions. Cropping lines are indicated 
in full-length blots of Supplementary Fig. S9. Hippocampal and erythrocytic ATIC, CPS2 and HPRT proteins 
showed significant expression level differences between the PLF and PSF groups, n = 5/group. (b) ATIC protein 
level showed moderate correlation with FST floating time. Correlation of (c) CPS2 and (d) HPRT protein levels 
with FST floating time was significant in the hippocampus and erythrocytes, n = 15. The cropped blots were 
used for the Fig. 4a. The gels have been run under the same experimental conditions. Protein expression levels 
were normalized with β -actin. Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (two-
tailed t-test). Pearson correlation coefficients (r) with p values are indicated in the correlation graphs.
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Discussion
In the present study we observed a heterogeneous pharmacological treatment response towards paroxetine in an 
inbred mouse strain. Using FST floating time, an indicative parameter for antidepressant-like activity7–9, we were 
able to stratify mouse sub-groups that differed in their response following chronic paroxetine administration. 
We submit that paroxetine-treated mice exhibiting no FST floating time difference with vehicle-treated mice are 
non-responsive towards SSRI treatment. We then examined metabolite and protein profiles in short-floating and 
long-floating mouse sub-groups representing paroxetine responders and non-responders, respectively, aiming to 
delineate molecular pathways associated with the SSRI response.
To examine the relevance of covariates drug levels, age and body weight gain were assessed. Paroxetine 
concentrations in whole brain and plasma were analyzed to check for a possible association of drug levels with 
antidepressant-like activity. Previous studies have reported a significant relationship between plasma levels and 
therapeutic response towards paroxetine10. In our study we did not find any paroxetine concentration differences 
between PLF and PSF mice in either whole brain or plasma and drug levels did not correlate with FST floating 
time. This suggests that paroxetine levels in whole brain and plasma are irrelevant for the observed differential 
drug treatment response in our long-term treatment setting. We also considered animal age and its relationship 
with paroxetine response. Age-dependent outcome of SSRI treatment has been assessed with regard to adverse 
effects of drug treatment by comparing antidepressant-induced behavioral response of juvenile or adolescent 
and adult rodents11,12. In the current study all mice reached adulthood prior to being subjected to experiments 
(>8 weeks). Although significant FST floating time differences were observed for mice between 18 and 20 weeks 
of age, no general age effect on FST floating time was detected. The relationship between body weight gain and 
chronic paroxetine treatment response was also investigated. Chronic paroxetine treatment induced a significant 
increase of body weight. However, body weight gain and drug treatment response for each group did not correlate 
significantly.
Figure 5. Correlation of ATIC, CPS2 and HPRT protein levels with clinical antidepressant treatment 
response. (a) Depression patients’ PBMCs collected after 4–6 weeks of antidepressant treatment were 
analyzed for ATIC, CPS2 and HPRT protein expression. ATIC and CPS2 protein levels significantly correlated 
with clinical antidepressant response, n = 17. (b) PBMCs from inpatients with depression were collected at 
admission. Cells were ex vivo cultivated and treated with paroxetine for 2 days. After treatment, ATIC and 
CPS2 protein levels significantly correlated with clinical antidepressant response, n = 32. Pearson correlation 
coefficients (r) with p values are indicated in the correlation graphs.
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To further characterize the PLF and PSF sub-groups we assessed female urine sniffing time, a behavioral 
parameter pertinent to evaluate SSRI treatment effect in mice13,14. While the PLF and PSF groups did not show 
any difference of female urine sniffing time prior to being treated with paroxetine, chronic paroxetine treatment 
induced a differential behavioral effect between the groups. This finding indicates that the different behavior 
between mice is not inherent, but is the result of chronic paroxetine treatment.
We performed metabolomics and proteomics analyses of the hippocampus to profile brain metabolite and 
protein differences between PLF and PSF mice.
In metabolomics analysis, significant metabolites enriched the pyrimidine metabolism as a differentially 
affected pathway between the two groups. Significant correlates of SAM signatures were investigated and revealed 
purine metabolism as an interacting sub-pathway. In proteomics analysis, purine/pyrimidine metabolism-related 
proteins were quantified with significant differences between the groups. Integrated metabolomics and proteom-
ics data implicate a differential effect of chronic paroxetine treatment on mouse hippocampal purine and pyrim-
idine metabolism.
Purine and pyrimidine metabolites and their receptors have previously been shown to be associated with various 
neuropsychiatric disorders. The anti-purinergic drug suramin was found to reverse autism-like behaviors and 
metabolism in mice15. Polymorphisms of the P2RX7 gene, which encodes a purinergic ion channel, have been 
associated with the development of MDD16 In addition, low brain purine levels were found in female depressed 
patients responding to treatment with the SSRI fluoxetine17. Uridine, a pyrimidine metabolite, has been shown to 
have antidepressant-like activities in mice18.
Hippocampal metabolome profiling also implicated other metabolites with elevated levels in PSF mice that 
have antidepressant-like activity. Folate has been shown to have an antidepressant-like effect in mice19 and low 
folate levels were found to be associated with MDD20 L-Methylfolate, the active metabolite of folate is used for 
patients with MDD who partially respond or do not respond to SSRIs21. Myo-inositol has been identified as a 
potential biomarker of SSRI treatment response and innate anxiety disorder22–24 and has been shown to have 
anxiolytic and antidepressant-like effects in both animals and humans25,26. Flavones are also known to have an 
antidepressant-like effect27,28. The elevated levels of folate, myo-inositol and flavones that we found in the hip-
pocampus of PSF mice might be of relevance for the favorable paroxetine response.
Peripheral specimens such as plasma and blood cells are the preferred biomarker sources for assessing the 
antidepressant treatment response in the clinical laboratory29–31. We compared the plasma metabolome of the 
two mouse sub-groups, PLF and PSF, at baseline and after 28 days of treatment (T0 and T4) with the aim of iden-
tifying differentially affected pathways and potential biomarker candidates in the periphery. Plasma metabolome 
changes over time resulted in group-specific profiles. Major metabolite level alterations and elevation of purine 
and pyrimidine metabolites were observed in the PSF group. In contrast, the plasma metabolome was minimally 
affected by chronic paroxetine treatment in the PLF group. Despite the fact that the glycine, serine and threonine 
metabolism pathway was specifically enriched as a sub-pathway of PLF group, significant metabolite level changes 
were observed in both sub-groups. We also found plasma metabolite biosignatures commonly regulated between 
the PLF and PSF groups. In particular levels of choline and threonine which are part of the glycine, serine and 
threonine metabolism pathway were changed both in the PLF and PSF groups after chronic paroxetine treatment. 
Thus, metabolites of glycine, serine and threonine metabolism do not seem to serve as a useful biosignature for 
the chronic paroxetine treatment response.
In contrast to hippocampal purine/pyrimidine metabolites, plasma metabolite level changes were not corre-
lated with FST floating time. Small plasma metabolite level differences between the PLF and PSF groups might be 
responsible for non-significant correlation. Despite non-significant correlation between plasma metabolite level 
changes and chronic paroxetine treatment response, group-specific analysis showed PSF-group specific pathway 
enrichment and significant metabolite changes.
In previous studies our -omics analyses revealed that energy metabolism-related pathways were significantly 
altered by chronic paroxetine- compared to vehicle-treated mice22,29. The current -omics analyses were performed 
to compare PLF and PSF mouse groups and identified purine and pyrimidine metabolisms as the main dis-
tinguishing pathways. However, ATP/ADP and NAD+/NADH ratios in the current study indicate that energy 
metabolism might also distinguish the PLF and PSF groups (see Supplementary Fig. S10).
Based on our integrated -omics data that implicate purine and pyrimidine metabolism pathways to be involved 
in paroxetine response we next wanted to corroborate these findings through the analysis of proteins that are part 
of these pathways. Based on the observed differences of carbamoyl phosphate and IMP levels between the PLF 
and PSF groups, ATIC, CPS2 and HPRT proteins were analyzed. CPS2 catalyzes early steps of carbamoyl phos-
phate synthesis in the pyrimidine biosynthesis pathway. ATIC and HPRT play a central role in synthesis and 
conversion of inosine monophosphate (IMP), the end product of the purine biosynthesis pathway. For pathway 
validation we chose hippocampus, prefrontal cortex and erythrocytes and compared ATIC, CPS2 and HPRT 
protein levels between the PLF and PSF groups. Western blot analyses revealed that hippocampal and eryth-
rocytic ATIC, CPS2 and HPRT proteins were differentially expressed between the two groups while prefrontal 
cortex protein expression showed no difference. Hippocampal and erythrocytic ATIC, CPS2 and HPRT protein 
levels were also highly correlated with FST floating time while no significant correlation was observed in the 
prefrontal cortex. This indicates that different purine and pyrimidine metabolism pathway activities between PLF 
and PSF groups might be specific for the hippocampus.
Interestingly, we observed an inverse relationship between hippocampal and erythrocytic protein expression 
for the three proteins. Inconsistent biosignature expression patterns in brain and peripheral tissues have been 
found in other cases related to psychiatric disorders. Brain and blood BDNF levels were inversely correlated 
in a genetic rat model of depression32. Brain and white blood cell p11 protein levels also showed an inverse 
relationship33. Inverse myo-inositol levels between hippocampus and plasma were also reported previously 
in mice chronically treated with paroxetine22. In the current study we found an inverse correlation trend for 
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carbamoyl phosphate and IMP levels between hippocampus and plasma. This might be caused by the observed 
inverse relationship of ATIC, CPS2 and HPRT enzyme expression levels between hippocampus and erythrocytes 
(see Supplementary Fig. S11).
To address the question whether the pathways for antidepressant response identified in the mouse are also 
relevant for patients’ response, PBMCs from antidepressant responder and non-responder patients were ana-
lyzed for ATIC, CPS2 and HPRT protein expressions. PBMCs collected after 4–6 weeks of antidepressant treat-
ment showed significant correlation between ATIC and CPS2 protein expression levels and HDRS score change 
between baseline and following chronic antidepressant treatment. Whereas PBMCs ATIC protein expression 
showed a similar pattern as the one observed in mouse erythrocytes, PBMCs CPS2 protein expression resembled 
that of mouse hippocampus.
In ex vivo experiments, PBMCs ATIC protein levels were negatively correlated with clinical antidepressant 
response. The observed discrepancy between in vivo and ex vivo PBMCs ATIC protein expression could be due 
to different treatment conditions (chronic vs. subchronic) and exposure to multiple types of drugs. PBMCs’ CPS2 
protein expression consistently showed negative correlation with mouse hippocampal protein expression both in 
in vivo and ex vivo. ATIC and CPS2 proteins may thus represent candidate biomarkers to predict clinical antide-
pressant treatment response. For HPRT protein, we failed to determine a significant correlation between clinical 
antidepressant response and PBMCs protein levels both in vivo and ex vivo.
Based on evidence from the literature microRNAs (miRNAs) may be relevant for the distinct regulation of 
purine/pyrimidine metabolisms in the PLF and PSF mouse groups. Feng et al. have shown that miR-1 and miR-
133a-3p regulate purine and pyrimidine metabolic pathways34 and the purine metabolism gene GART is regulated 
by 16 miRNAs35. Since SSRIs impact miRNA levels36 this may explain the observed differences in the purine and 
pyrimidine metabolisms upon chronic paroxetine treatment.
The current study used wild-type stress naïve DBA/2J mice to investigate the pharmacological hetero-
geneity of the antidepressant response. Wild-type stress naïve rodents have been used previously to evaluate 
antidepressant-like effects37–39. An extension of our studies using an animal model with a depression-like phe-
notype would further validate the identified pathways affected by the antidepressant treatment response and add 
relevant information for the antidepressant treatment of patients.
What roles purine and pyrimidine metabolic pathways play in the underlying mechanism of SSRI response 
requires further studies with compounds able to modulate pathway activity. Pathway modulators may lead to 
novel drugs with antidepressant activities. In addition, purine and pyrimidine metabolic pathway activities could 
be used as a biosignature for the antidepressant treatment response. With biomarkers for antidepressant treat-
ment response patient sub-groups can be stratified and this will render clinical decision more objective. Whether 
the identified pathways can lead to predictive biosignatures for antidepressant treatment response remains to be 
investigated.
Methods
Animal Housing and Husbandry. The experiments were carried out with male DBA/2J mice (Charles 
River Laboratories, Chatillon-sur-Chalaronne, France). All animals were between 8–10 weeks old and single 
housed for at least one week prior to the beginning of the experiments. Mice were held under normal light and 
temperature conditions (12 light: 12 dark light cycle, lights on at 7 pm, temperature at 23 ± 2 °C, and humidity 
at 55 ± 5%) with standard bedding and nesting material, in polycarbonate cages (21 × 15 × 14 cm). Water and 
Altromin 1324 standard mouse chow (Altromin GmbH, Lage, Germany) were provided ad libitum. All pro-
cedures were carried out in accordance with the European Communities Council Directive 2010/63/EU and 
approved by the committee for the Care and Use of Laboratory animals of the Government of Upper Bavaria, 
Germany.
Drug Administration. In preliminary studies we investigated the minimum effective dosage of paroxetine 
in DBA/2J mice to minimize drug-induced side effects. Two doses of paroxetine pills (either 2 × 1 mg/kg/day or 
2 × 5 mg/kg/day) were given to mice for 28 days. In forced swim test (FST), only higher dose (2 × 5 mg/kg/day) 
of paroxetine treatment induced a significant floating time increase. Therefore, mice were treated with vehicle 
or 5 mg/kg paroxetine pills (Paroxetine hydrochloride; Carbone Scientific, London, UK) for 28 days twice a day. 
Animals were randomly distributed to the vehicle or paroxetine treated experimental groups. Vehicle or par-
oxetine was voluntarily self-administered via customized palatable pellets (40 mg PQPellets, Phenoquest AG, 
Martinsried, Germany). Animals that did not take the treatment properly were excluded from further analysis.
Mouse brain and blood collection. Blood was collected at least one month before commencing paroxe-
tine treatment from retro-orbital puncture and after 28 days of paroxetine treatment through cardiac puncture 
or trunk blood. On day 29, the animals were subjected to a FST and sacrificed. Trunk blood and brains of the 
animals were collected and stored at − 80 °C until further use. Blood was centrifuged to separate plasma and 
erythrocytes (1300 g, 10 min, 4 °C) before storage.
Behavioral Analyses. Forced Swim Test. Mice were placed into a glass beaker (height 24 cm, diameter 
13 cm) filled with water (21 ± 1 °C) up to a height of 15 cm, so that the animals were unable to reach the ground 
or escape for 6 min testing. Main parameter of interest is floating time scored by an experienced observer blind 
to treatment.
Female urine sniffing test. Mice were habituated to a cotton swab inserted into their home cage for 1 h prior 
to testing. Mice were exposed to a sterile cotton swab dipped into water for 3 min and after a 45 min inter trial 
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interval. Then they were exposed to a sterile cotton swab dipped in estrous female urine from the same strain. 
Total sniffing time was recorded.
Hierarchical Clustering Analysis (HCA). HCA is a method to build and split different cluster hierarchies. 
It has been applied to identify sub-groups of cells and animals based on marker protein expression or behavioral 
parameters40,41. HCA was carried out with SPSS (SPSS version 21, IBM SPSS Inc., Chicago, IL, USA) to separate 
paroxetine-treated sub-groups of mice based on FST floating time. Animals with extreme FST floating times were 
selected from the PLF and PSF groups for -omics analyses. Proteomics and metabolomics profiles from individual 
animals were used with no data pooling.
Paroxetine Measurements. Mouse whole brains were homogenized in a fivefold volume of phosphate 
buffered saline (PBS) containing “Complete Protease Inhibitor Cocktail Tablets” (Roche, Penzberg, Germany) 
using a Dispomix Drive (Medic Tools AG, Zug, Switzerland). All samples were prepared using Ostro protein 
precipitation and phospholipid removal plates (Waters, Eschborn, Germany). Plasma and brain homogenates 
were analyzed by LC-MSMS using an Agilent 1100 Series (Agilent, Waldbronn, Germany) liquid chromatograph 
interfaced with an Applied Biosystems API 4000 (ABSciex, Darmstadt, Germany) triple quadrupole mass spec-
trometer. Deuterated paroxetine (Paro-D6) was used as internal standard. Five μ l samples were loaded and gra-
dient eluted from an Accucore RP-MS 2.6 μ m column (2.1 × 50 mm, Thermo Scientific, Dreieich, Germany) at 
a flow rate of 0.3 ml/min and 30 °C (eluent A: methanol, 10 mM ammonium formate, 0.1% formic acid; eluent 
B: 10 mM ammonium formate, 0.1% formic acid). Gradient: 0–0.5 min 20% A, 0.5–2 min 20–90% A, 1 min held 
at 90% A, 3–3.5 min 90–20% A and 3.5–8 min 20% A. The ion source was operated in positive mode at 500 °C 
and multiple reaction monitoring (MRM) collision-induced dissociation (CID) was performed using nitrogen 
collision gas. The collision energy was set to 29 V for paroxetine and 33 V for Paro-D6. The transitions monitored 
during analysis were m/z 330 → 192 for paroxetine and m/z 336 → 198 for Paro-D6.
Proteomics Analysis. Mouse hippocampus was homogenized in a buffer containing 2M NaCl, 10 mM 
HEPES/NaOH, 1 mM EDTA and protease inhibitor cocktail tablets (Roche Diagnostics, Mannheim, Germany) 
and phosphatase inhibitors (Sigma, St. Louis, MO, USA). Homogenates were sonicated with an ultra-sonicator 
(Branson, Danbury, CT, USA) and centrifuged (16100 g, 20 min, 4 °C). The protein concentration was determined 
by Bradford assay.
Protein extracts were mixed with equal amounts of 15N-labeled DBA/2 mouse hippocampal protein extract24. 
Fourty μ g of 14N- 15N hippocampal protein mixture was separated in a 10% SDS-PAGE gel and stained with 
Coomassie Brilliant Blue R-250 (BioRad, Hercules, CA, USA) overnight. After destaining and cutting the gel 
lane into slices, tryptic peptides were produced and extracted as previously described42. Extracted peptides were 
analyzed by liquid chromatography-electrospray tandem mass spectrometry (LC-MS/MS) using a nanoflow 
HPLC-2D system (Eksigent, Dublin, California) coupled online to an LTQ-Orbitrap mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany). Protein identification and quantitation were performed as described 
previously22.
Metabolomics Analysis. Mouse brain and plasma metabolites were extracted and analyzed with targeted 
metabolomics as previously described43. Animals from the same cohort were used for all metabolomics analyses.
Paroxetine treatment of patient peripheral blood mononuclear cells. Blood of patients with major 
depression disorder was collected between 08:00 and 09:00 h within 5 days after admittance. PBMCs were pre-
pared as described previously44. Cells were treated with 120 ng/ml paroxetine for 2 days according to the consen-
sus guidelines for therapeutic drug monitoring in psychiatry45.
Protein level quantitation in cultivated PBMCs. In ex vivo cultivated PBMCs, ATIC, CPS2, HPRT and 
β -actin protein levels were detected and quantitated with an automated capillary immunoassay system, Simple 
WesternTM (ProteinSimple, Santa Clara, CA, USA). PBMCs lysates were prepared according to manufacturer’s 
instruction. All following steps were fully automated. Protein quantitation data were normalized with β -actin.
Western Blot Analysis. Mouse hippocampus, prefrontal cortex and erythrocytes were homogenized with 
the same buffer used for proteomics sample preparation, or RIPA buffer containing protease inhibitor cocktail tab-
lets (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitors (Sigma, St. Louis, MO, USA). Patient 
PBMCs were homogenized with RIPA buffer containing protease and phosphatase inhibitors. Homogenates were 
sonicated and centrifuged (16100 g, 20 min, 4 °C). Bradford assay was used to quantify extracted protein concen-
tration. Proteins were separated in 10–15% gradient SDS-PAGE gels. Subsequently, they were transferred to a 
PVDF membrane (Millipore, Billerica, MA, USA). After blotting, the membrane was blocked with 5% skim milk 
solution for 1 h at room temperature and incubated with either anti-aminoimidazole-4-carboxamide ribonucleo-
tide transformylase/IMP cyclohydrolase (ATIC) antibody (1:500, Santa Cruz, Dallas, TX, USA) or anti-carbamoyl 
phosphate synthase 2 (CPS2) antibody (1:500, Santa Cruz, Dallas, TX, USA) or anti-hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) antibody (1:500, Sigma, St. Louis, MO, USA) or β -actin antibody (1:4000, Sigma, 
St. Louis, MO, USA) at 4 °C overnight. The membranes were washed and then incubated with horseradish perox-
idase (HRP) conjugated-secondary antibodies. The blots were developed with LuminataTM Forte Western HRP 
Substrate (Millipore, Billerica, MA, USA). Images were acquired by ChemiDocTM MP imaging system (Bio-Rad 
Laboratories, Munich, Germany). Densitometric data analyses were carried out with ImageJ software (National 
Institute of Health, USA).
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Statistical Analysis. Statistical analysis of behavioral data in FST/FUST and covariates were performed with 
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Student t-test, one-way or two-way ANOVA 
were used to assess statistical significance between groups. Pearson correlation coefficients (r) with p values were 
used to evaluate correlation between floating time and body weight gain. For the identification of significantly 
altered metabolites, metabolite peak intensities were median and auto-scaled normalized. Metabolites with miss-
ing values, 30 for the hippocampus and 27 for the prefrontal cortex in all replicates, were excluded from data 
analysis. Significant analysis of microarrays (and metabolites) (SAM) method was used to identify significantly 
altered metabolites (q < 0.05, FDR < 0.1).
Significantly altered metabolites were subjected to pathway enrichment analysis of MetaboAnalyst (http://
www.metaboanalyst.ca) to identify differentially affected pathways between the PLF and PSF groups. Pathways 
with Holm adjusted p < 0.05 and FDR < 0.05 were considered significantly affected. To identify sub-pathways 
interacting with a differentially affected pathway between the PLF and PSF groups, correlates of each SAM signa-
ture were combined and used to enrich relevant metabolic pathways using MetaboAnalyst (Pearson correlation 
coefficients (r) > 0.7, FDR < 0.1). Pathways with Holm adjusted p < 0.05 and FDR < 0.05 were considered signifi-
cant. CPS2, HPRT and β -actin Western blot data were also analyzed with GraphPad Prism 5. Two-tailed t-test was 
used to evaluate the difference between the PLF and PSF groups. Data were expressed as the mean ± the standard 
error of the mean (SEM). Statistical data were considered significant at p < 0.05. D’Agostino & Pearson omnibus 
normality test was used to check normal distribution of the data.
Patient samples. For in vivo and ex vivo studies, two distinct PBMC batches from different individuals 
were chosen. Peripheral blood mononuclear cells (PBMCs) obtained from 17 participants of the Munich 
Antidepressant Response Signature (MARS) study were included for assessing protein expression levels (see 
Supplementary Table S1). PBMCs from 32 individuals were subjected to ex vivo cultivation and paroxetine treat-
ment (see Supplementary Table S2). Diagnosis was conducted according to DSM-IV criteria, and all partici-
pants were diagnosed as having MDD (see Supplementary Table S3). Depression severity was evaluated using the 
21-item Hamilton Depression Rating Scale (HDRS). Responder and non-responder patients were classified based 
on clinical antidepressant treatment response corresponding to minimal 50% reduction in HDRS score between 
baseline (T0) and after 6 weeks of admission (T6). The Munich Antidepressant Response Signature (MARS) study 
was approved by the local ethics committee of the Ludwig-Maximilians-University Munich, Germany (approval 
no. 318/00), and the study was carried out in accordance with the principles of Good Clinical Practice and with 
the latest edition of the Declaration of Helsinki. All patients provided written informed consent before study 
inclusion.
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